Methodology

Details of the EUHASS data collection and reporting system

Surveillance began on 1 October 2008.

Patients included in the surveillance

Haemophilia A
Haemophilia B
von Willebrand’s disease: type 1 severe (<15% VWF:RiCo), type 2, type 3, type unknown
Factor I deficiency: Afibrinogenemia (<10mg/dl), Hypofibrinogenemia (10-50 mg/dl), Dysfibrinogenemia (50-150 mg/dl)
Factor II deficiency
Factor V deficiency
Factor VII deficiency
Factor X deficiency
Factor XI deficiency
Factor XIII deficiency
Alpha 2 antiplasmin deficiency
Combined Factor V+VIII deficiency
Combined Factor II, VII, IX, X deficiency
Acquired haemophilia A†
Acquired VWD†
Glanzmann’s thrombasthenia†
Bernard-Soulier syndrome†
Platelet storage pool disease†

†Diagnoses added to surveillance from 1 July 2012

Patients excluded from surveillance

Patients with acquired clotting factor deficiencies, unless they are Acquired haemophilia or Acquired VWD.

Events to be reported during surveillance

- Allergic or other acute event
- Transfusion transmitted infections
- Inhibitors (antibodies against the coagulation factor)
- Thromboses
- New cardiovascular events
- New malignancy diagnoses
- Neurological events‌†
- Deaths
- Unexpected Poor Efficacy*
- Other Adverse Event Possibly Related to Concentrate*

*Reporting of these events was from pilot centres only 1 October 2010 – 30 June 2012, reporting expanded to all centres from 1 July 2012.

‌†Event category added February 2018

Population data

At the end of each complete year of surveillance participating centres provide data on the number of patients registered with them and the clotting factor concentrates used to treat them. Centres may report usage of unlicensed clinical trial products (no product name is reported) as well as licensed named products.